首页> 外文期刊>Regulatory peptides. >Effect of des-aspartate-angiotensin I on the actions of angiotensin II in the isolated renal and mesenteric vasculature of hypertensive and STZ-induced diabetic rats.
【24h】

Effect of des-aspartate-angiotensin I on the actions of angiotensin II in the isolated renal and mesenteric vasculature of hypertensive and STZ-induced diabetic rats.

机译:天门冬氨酸血管紧张素I对高血压和STZ诱导的糖尿病大鼠孤立的肾脏和肠系膜脉管系统中血管紧张素II的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The present study investigated the action of des-aspartate-angiotensin I (DAA-I) on the pressor action of angiotensin II in the renal and mesenteric vasculature of WKY, SHR and streptozotocin (STZ)-induced diabetic rats. Angiotensin II-induced a dose-dependent pressor response in the renal vasculature. Compared to the WKY, the pressor response was enhanced in the SHR and reduced in the STZ-induced diabetic rat. DAA-I attenuated the angiotensin II pressor action in renal vasculature of WKY and SHR. The attenuation was observed for DAA-I concentration as low as 10(-18) M and was more prominent in SHR. However, the ability of DAA-I to reduce angiotensin II response was lost in the STZ-induced diabetic kidney. Instead, enhancement of angiotensin II pressor response was seen at the lower doses of the octapeptide. The effect of DAA-I was not inhibited by PD123319, an AT(2) receptor antagonist, and indomethacin, a cyclo-oxygenase inhibitor in both WKY and SHR, indicating that its action was not mediated by angiotensin AT(2) receptor and prostaglandins. The pressor responses to angiotensin II in mesenteric vascular bed were also dose-dependent but smaller in magnitude compared to the renal vasculature. The responses were significantly smaller in SHR but no significant difference was observed between STZ-induced diabetic and WKY rat. Similarly, PD123319 and indomethacin had no effect on the action of DAA-I. The findings reiterate a regulatory role for DAA-I in vascular bed of the kidney and mesentery. By being active at circulating level, DAA-I subserves a physiological role. This function appears to be present in animals with diseased state of hypertension and diabetes. It is likely that DAA-I functions are modified to accommodate the ongoing vascular remodeling.
机译:本研究调查了天冬氨酸-血管紧张素I(DAA-I)对WKY,SHR和链脲佐菌素(STZ)诱导的糖尿病大鼠的肾和肠系膜脉管系统中血管紧张素II的加压作用。血管紧张素II诱导肾血管中的剂量依赖性升压反应。与WKY相比,SHR的升压反应增强,STZ诱导的糖尿病大鼠降压反应降低。 DAA-I减弱了WKY和SHR的肾血管中的血管紧张素II升压作用。对于低至10(-18)M的DAA-1浓度观察到衰减,并且在SHR中更为明显。但是,在STZ诱导的糖尿病肾中,DAA-1降低血管紧张素II反应的能力已丧失。取而代之的是,在较低剂量的八肽时,血管紧张素II的升压反应增强。 DAA-1的作用不受AT(2)受体拮抗剂PD123319和WKY和SHR中的环加氧酶抑制剂吲哚美辛的抑制,表明其作用不受血管紧张素AT(2)受体和前列腺素的介导。 。肠系膜血管床中对血管紧张素II的升压反应也与剂量有关,但与肾脉管系统相比其幅度较小。 SHR的反应明显较小,但在STZ诱导的糖尿病大鼠和WKY大鼠之间未观察到显着差异。同样,PD123319和消炎痛对DAA-1的作用没有影响。该发现重申了DAA-1在肾脏和肠系膜血管床中的调节作用。通过在循环水平上活跃,DAA-1发挥了生理作用。该功能似乎在患有高血压和糖尿病的动物中存在。 DAA-I功能可能已被修改以适应正在进行的血管重塑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号